Navigation Links
Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Date:12/7/2011

REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler (GP MDI; PT001) in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent® HFA Inhalation Aerosol, a short-acting muscarinic antagonist given four times a day (QID). All doses of GP MDI tested produced statistically significant improvements in lung function (FEV1 AUC 0-12)(1) compared to placebo (p<0.0001). Further, doses of PT001 were identified that were non-inferior to Atrovent HFA. PT001 was well tolerated and no safety concerns were identified. This study complements Pearl's previous assessment of PT001's clinical profile relative to well established marketed muscarinic antagonists(2), and provides additional dose ranging data for glycopyrrolate component of Pearl's LAMA/LABA combination product, PT003. Detailed results of this Phase 2b study of PT001 will be presented at a future conference.

Dr. Colin Reisner, chief medical officer and executive vice president of clinical development for Pearl Therapeutics commented, "This Phase 2b study provides important information about the safety and efficacy of GP MDI, the LAMA component of PT003, our lead combination bronchodilator candidate for the treatment of COPD. Further, the activity profile of GP MDI in this study is consistent with that observed in two previously reported studies and supports the BID dosing that we believe will provide the best symptom relief for patients with moderate-to-severe COPD."

"A significant part of the very large COPD market is driven by the use of BID LABAs and inhaled corticosteroids.  However, a rapid-acting, BID LAMA to complement
'/>"/>

SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
2. Anthera Announces Last Patient Enrolled in PEARL-SC Study
3. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
4. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
5. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
6. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
7. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
10. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
11. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, Calif. , Oct. 20, 2014  PneumRx, ... of interventional pulmonology, today announced completion of enrollment in ... The RENEW Clinical Study is the FDA-approved IDE pivotal ... for severe emphysema. It was anticipated that ... in February 2013, would take until the end of ...
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Data Expected in the Third Quarter --, SAN ... ), a biotechnology company focused on the development of,compounds ... has completed the last patient visit in its carotid ... analyzed to determine,VIA-2291,s effect on inflammation, and the company ...
... TOKYO, July 10 Sosei Group Corporation,("Sosei"; TSE ... completion of a Japanese Phase III clinical trial ... acquired the,exclusive distribution rights to the product in ... was designed to evaluate the safety and prevented,pregnancy ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Sosei Announces Completion of Phase III Trial for NorLevo(R) 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... special MRI methods, researchers have identified a pattern of ... (MCI) that indicates a greater likelihood of progression to ... edition of Radiology . , "Previously, this ... probable Alzheimer,s disease," said the study,s lead author, Linda ...
... Inc., today filed a formal protest and requested a ... managed behavioral health care contract RFP 09-630-7903-0001, which was ... New Mexico believes a stay is in the best ... consumers who will be adversely affected by the potential ...
... Feb. 9 The following is a statement from ... Director, American Public Health Association:"At a time when more ... to the nation,s public health system as a way ... (APHA) is thoroughly disappointed with the Senate,s decision to ...
... Inc. (NYSE Alternext: IMM) today announced results for its ... months ended December 31, 2008, revenues were $563,000, as ... 31, 2007. The decrease was primarily attributable to ... agreement. Loss from operations for the three months ...
... to Host Phoenix Arizona Celebrity GalaCOSTA MESA, Calif., Feb. 9 ... Dodgers, will co-host a celebrity casino event to benefit families ... Oakland A,s and World Series MVP. Kemp also serves ... (TACA). Kemp and Stewart host the celebrity-packed evening Ante ...
... ARLINGTON, Va., Feb. 9 BioInformatics, LLC ( http://www.gene2drug.com ... serving the life science industry -- will be a ... ( www.consumergeneticsshow.com ) in Boston, MA at the Hynes ... will also be exhibiting at the show. The ...
Cached Medicine News:Health News:MRI shows brain atrophy pattern that predicts Alzheimer's 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 3Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 4Health News:APHA Urges Congress to Include Public Health Provision in Stimulus Bill 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 3Health News:Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism 2Health News:BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009 2
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... ™ Airway., ,The LMA Flexible™ ... allows it to be positioned away ... a good seal. This makes it ... surgery, or other procedures where the ...
... The Most Versatile LMA™ Airway., ,The ... airway. The double cuff design enables seal ... be achieved. The drain tube separates the ... with the flexible airway tube, enable longer ...
Medicine Products: